Long-acting beta-agonists (LABAs)

LABAs are inhaled bronchodilators with duration of action of at least 12 hours.

 

• They should not be used as monotherapy in asthma but only in combination with ICSs. These product combinations are indicated in moderate or severe persistent asthma (step 3 care or higher in children aged 5 years or older). LABA and ICS should not be prescribed as individual inhalers for pediatric and adolescent patients.
• LABA-containing products carry a Black Box warning that should be discussed with parents. These products should be used only for patients whose asthma is not well-controlled with low- to medium-dose ICSs. Patients taking LABA-containing products should be closely monitored for control to consider a step down to ICSs if appropriate.